HIV/HCV Co-Infection Case

Slides:



Advertisements
Similar presentations
HIV/HCV Coinfection News – HCV Protease Inhibitors
Advertisements

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.
Treatment-experienced HCV genotype 1 patients Bill Sievert Sally Bell.
Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis C What’s New Alan Kilby, M.D. Portland Gastroenterology Center Maine Medical Center VTC Sept 27, 2013.
Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.
Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.
Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Management of side effects Cirrhotic on telaprevir Vincent LEROY Clinique Universitaire d’Hépato-Gastroentérologie INSERM U823 CHU de Grenoble.
Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
Update on the HCV Antiviral Pipeline Todd S. Wills, MD SPNS HCV Treatment Expansion Initiative Evaluation and Technical Assistance Center Infectious Disease.
Xavier Forns, MD Liver Unit, Hospital Clínic IDIBAPS and CIBREHD Barcelona, Octubre 2013 Tratamiento de poblaciones especiales Curso de Residentes AEEH.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a.
Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.
How to avoid a resistance issue with the first generation protease inhibitors ? O. Lada PHD Service d’Hépatologie et INSERM CRB3, AP-HP Hopital Beaujon,
Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.
Hepatitis C Nonresponders
Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.
36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 –only qualitative PCR available : positive at.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
به نام خداوند بخشنده مهربان. Treatment of HIV/HCV & HIV/HBV coinfection Dr. Davoudi Infectious diseases specialist Antimicrobial research center Mazandaran.
ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Lesson 2: Special Considerations When Treating HIV/HCV Co-infection
Diagnostics in hepatitis C: The end of response-guided therapy?
Treatment Outcomes for Chronic Hepatitis C Infection with Direct Acting Antivirals among Inmates in Federal Corrections Smith JM, Boudreau H, Kom E, Tremblay.
No HBV or HIV co-infection
Pipeline & HCV UK-CAB 31 January 2009.
Failure to achieve SVR on No HBV or HIV co-infection
Future Trials of Hepatitis C Therapy in the HIV Co-infected
Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Resistance to Direct Acting Antiviral Therapy
Treating Hep C with Novel Agents
Expanding the Universe of Viral Hepatitis Treaters
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
The Aging Liver in the Aging HIV and HCV Patients
Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC.
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
More Than Treatment.
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
HCV Protease Inhibitors in Clinical Practice
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
Diagnostics in hepatitis C: The end of response-guided therapy?
GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II
Care of the Treatment-naive Patient With HCV/HIV Coinfection
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II
PI-Based HCV-1 Therapy: Reasons to Hold Off
The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project Summary Webinar for Demonstration Clinics.
Hepatitis C: After the Diagnosis
‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?  Andres Duarte-Rojo, Elizabeth Jenny Heathcote,
A Guideline-Based Approach to HCV Care
HCV Protease Inhibitors in Clinical Practice
What do data in monoinfection mean in relation to co-infection?
Volume 142, Issue 6, Pages (May 2012)
What Does the Future Hold and What Will It Mean for Patients?
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:
Genetic Factors and Hepatitis C Virus Infection
Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.
Lesson 2: Special Considerations When Treating HIV/HCV Co-infection
Presentation transcript:

HIV/HCV Co-Infection Case

Disclosures

Treatment History

Laboratory Values

SVR in HIV/HCV Pts According to IL28B

Factors Associated with SVR in HIV HCV Treated Pts.

IL-28B and DAA

Laboratory Values

Any other issues that need to be addressed before treatment?

Insulin Resistance Influences Response to Treatment with PegIFN/RBV in HIV/HCV Co-Infected Patients

Insulin Resistance Influences Response to Re-Treatment with PegIFN/RBV in HIV/HCV Co-Infected Patients

Multi-variable Analysis Outcome = SVR

Does Vitamin D Play a Role?

Does Vitamin D Play a Role?

June 2011

What do you recommend to this HIV-HCV cirrhotic patient?

Is the patient’s HIV regimen compatible with DAA?

DAA and co-infected patients

Telaprevir and co-infected: Study 110

Telaprevir and co-infected: Study 110

Boceprevir and co-infected

Boceprevir and co-infected

Pharmacokinetic interactions

Summer 2011

HCV viral load

CBC

Cytopenias and DAA

What would you recommend?

Growth factors and hepatitis C treatment

Growth factors and hepatitis C treatment

EPO

G-CSF

Thrombopoietic agents

CBC

January 2012

RGT

Telaprevir response guided therapy (RGT)

February 13th 2012

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.